Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis
Author(s) -
Stephanie L. Barnes,
Yuyi You,
Ting Shen,
Todd A. Hardy,
Clare L. Fraser,
Stephen Reddel,
Fabienne Brilot,
Sudarshini Ramanathan,
Alexander Klistorner,
Con Yiannikas
Publication year - 2021
Publication title -
multiple sclerosis journal - experimental translational and clinical
Language(s) - English
Resource type - Journals
ISSN - 2055-2173
DOI - 10.1177/20552173211063126
Subject(s) - neuromyelitis optica , optic neuritis , multiple sclerosis , myelin oligodendrocyte glycoprotein , medicine , optic nerve , ophthalmology , nerve fiber layer , pathology , immunology , experimental autoimmune encephalomyelitis
Background Optic neuritis (ON) occurs in immune-mediated disorders including multiple sclerosis (MS), aquaporin-4 antibody-positive (AQP4) neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination (MOGAD). Accurate determination of aetiology is critical for appropriate treatment and prognostication.Objective To evaluate demyelination and axonal loss in MOG-ON to facilitate differentiation from MS-ON and AQP4-ON.Methods 15 MOGAD patients with previous ON (25 eyes) underwent multifocal visual evoked potential (mfVEP) recordings and optical coherence tomography scans. Comparison was made to previously reported MS patients ( n = 67, 69 eyes) and AQP4-NMOSD patients ( n = 15, 23 eyes) with prior ON and healthy controls ( n = 37, 74 eyes).Results MOG-ON patients had less retinal nerve fibre layer (RNFL) loss than AQP4-ON patients ( p < 0.05) and less mfVEP latency prolongation than MS-ON patients ( p < 0.01). Number of ON episodes in MOGAD was associated with reduced RNFL thickness (global, p = 0.07; temporal, p < 0.001) and mfVEP amplitude ( p < 0.001). There was no abnormality in non-ON eyes.Conclusions Our study demonstrated a distinct pattern of damage in MOG-ON compared to AQP4-ON and MS-ON. ON in MOGAD produces less axonal loss than AQP4-NMOSD. Damage accumulates with relapses, supporting the role of maintenance immunosuppression to induce remission. Compared to MS, MOGAD causes less demyelination.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom